Senti Biosciences (NASDAQ:SNTI) Stock Price Down 8.7%

Senti Biosciences, Inc. (NASDAQ:SNTI)’s share price dropped 8.7% during mid-day trading on Monday . The company traded as low as $0.27 and last traded at $0.28. Approximately 91,570 shares changed hands during mid-day trading, a decline of 16% from the average daily volume of 108,970 shares. The stock had previously closed at $0.31.

Senti Biosciences Price Performance

The stock has a market capitalization of $12.85 million, a PE ratio of -0.18 and a beta of 2.96. The business’s fifty day moving average price is $0.38 and its 200-day moving average price is $0.41.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter. Senti Biosciences had a negative return on equity of 74.59% and a negative net margin of 2,692.82%. On average, analysts expect that Senti Biosciences, Inc. will post -1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Senti Biosciences

Institutional investors and hedge funds have recently modified their holdings of the company. ARK Investment Management LLC raised its stake in Senti Biosciences by 7.9% in the fourth quarter. ARK Investment Management LLC now owns 1,969,860 shares of the company’s stock valued at $1,300,000 after purchasing an additional 143,785 shares in the last quarter. TD Asset Management Inc raised its stake in Senti Biosciences by 88.4% in the third quarter. TD Asset Management Inc now owns 241,208 shares of the company’s stock valued at $102,000 after purchasing an additional 113,172 shares in the last quarter. Finally, 8VC GP I LLC purchased a new stake in Senti Biosciences in the fourth quarter valued at approximately $1,675,000. 25.73% of the stock is owned by hedge funds and other institutional investors.

About Senti Biosciences

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.